Article Text

PDF
Comparison of Testosterone, Alendronate, and a Combination of Both Therapies in Men with Low Bone Mineral Density
  1. Brian J. Welch,
  2. Margo A. Denke,
  3. Asra Kermani,
  4. Beverley Adams-Huet,
  5. Nina M. Gazmen,
  6. Ugis Gruntmanis
  1. From the Division of Endocrinology (B.J.W., U.G.) and Department of Clinical Sciences (B.A.-H.), University of Texas Southwestern Medical Center, Dallas, TX; Division of Endocrinology (M.A.D., A.K., U.G.) and Department of Radiology (N.M.G.), Dallas Veterans Affairs Medical Center, Dallas, TX.
  1. Presented in abstract form at the 26th Annual Meeting of the American Society of Bone and Mineral Research (ASBMR) in Seattle, WA, October 1-5, 2004.
  2. Address correspondence to: Dr. Ugis Gruntmanis, 5323 Harry Hines Blvd, Dallas, TX 75390-8857; e-mail: ugis.gruntmanis{at}utsouthwestern.edu.

Abstract

Background Both bisphosphonates and testosterone are known to improve bone mineral density (BMD) in men with low bone mass, but whether combination therapy is superior to these agents used alone is not clear. We compared the changes in lumbar spine BMD when men with low bone mass were treated with each agent alone or as combination therapy.

Methods In a retrospective study, we analyzed serum and BMD data from 149 men who had been evaluated in the Endocrinology Clinic at the Dallas Veterans Affairs Medical Center, Dallas, Texas. The subjects were divided into three cohorts: 59 men receiving testosterone therapy alone, 68 men receiving alendronate therapy alone, and 22 receiving combination therapy.

Results Compared with the baseline values, the lumbar spine and BMD increased significantly in each of the testosterone, alendronate, and combination therapy cohorts (median annualized rate of change: 2.1% [p < .001], 2.6% [p < .001], and 2.5% [p = .04], respectively). The combination therapy group did not demonstrate any additional increase in BMD at the lumbar spine or total hip compared with either agent alone. The results did not change after adjusting for differences in baseline weight, age, BMD, or baseline testosterone level.

Conclusion The results suggest that the combination of testosterone and alendronate does not appear to be superior to single-drug therapy in our patient population.

Key words
  • testosterone
  • alendronate
  • bone density

Statistics from Altmetric.com

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.